ORIC Pharmaceuticals, Inc. [●] Shares of Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • November 10th, 2020 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“JPM”), Citigroup Global Markets Inc. (“Citi”) and Jefferies LLC (“Jefferies”) are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
ORIC PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • February 28th, 2020 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • May 6th, 2021 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
BRITANNIA POINTE GRAND BUSINESS PARK LEASELease • February 28th, 2020 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and ORIC PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 21st, 2022 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 21, 2022, between ORIC Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the “Purchaser”).
ORIC PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENTStock Purchase Agreement • January 22nd, 2024 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Stock Purchase Agreement (the “Agreement”) is made as of January 20, 2024 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers”).
AMENDMENT NO. 1 TO THE LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • May 6th, 2024 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO THE LICENSE AND COLLABORATION AGREEMENT (this “Amendment No. 1”), effective March 20, 2024 (the “Amendment No. 1 Effective Date”), is entered into by and between Voronoi Inc., a limited corporation duly established under the Republic of Korea’s commercial code, having offices at S. 18th F, Songdogwahak-ro 32[IT Center], Yeonsu-gu, Incheon, Korea (“Voronoi”) and ORIC Pharmaceuticals, Inc., a Delaware corporation having business offices at 240 East Grand Ave., 2nd Floor, South San Francisco, CA 94080 (“ORIC”). Voronoi and ORIC are each referred to herein individually as a “Party” and collectively as the “Parties.”
ContractEmployment Agreement • February 28th, 2020 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This letter agreement (the “Agreement”) is entered into between you and ORIC Pharmaceuticals, Inc. (the “Company” or “we”), effective as of March 1, 2020 (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
ContractEmployment Agreement • February 28th, 2020 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This letter agreement (the “Agreement”) is entered into between you and ORIC Pharmaceuticals, Inc. (the “Company” or “we”), effective as of March 1, 2020 (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
ContractEmployment Agreement • February 28th, 2020 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This letter agreement (the “Agreement”) is entered into between you and ORIC Pharmaceuticals, Inc. (the “Company” or “we”), effective as of March 1, 2020 (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
LICENSE AND COLLABORATION AGREEMENT BETWEEN ORIC PHARMACEUTICALS, INC. AND VORONOI INC.License and Collaboration Agreement • May 9th, 2022 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) dated as of 19th day of October, 2020 (“Effective Date”), is entered into between Voronoi Inc., a limited corporation duly established under the Republic of Korea’s commercial code having offices at S 18th F, Songdogwahak-ro 32[IT Center], Yeonsu-gu, Incheon, Korea (“Voronoi”) and ORIC Pharmaceuticals, Inc., a Delaware corporation having business offices at 240 East Grand Ave, 2nd Floor, South San Francisco, CA, 94080 (“ORIC”).
FIRST AMENDMENT TO LEASELease • August 16th, 2021 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of August 12, 2021, by and between BRITANNIA POINTE GRAND LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and ORIC PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
LICENSE AGREEMENTLicense Agreement • May 9th, 2022 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LICENSE AGREEMENT (this “Agreement”), entered into as of August 3, 2020 (the “Effective Date”), is entered into by and between Mirati Therapeutics, Inc., a Delaware corporation having business offices at 9393 Towne Centre Drive, Suite 200, San Diego, California 92121 (“Mirati”), and ORIC Pharmaceuticals, Inc., a Delaware corporation having business offices at 240 East Grand Ave, 2nd Floor, South San Francisco, CA, 94080 (“ORIC”).
ORIC PHARMACEUTICALS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 27th, 2023 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (the “Agreement”) is made as of June 24, 2023 (the “Effective Date”), by and among ORIC Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers”).
